Most of the latest Multiple Sclerosis treatments cater to relapsing and remitting MS patients. Until Roche’s blockbuster drug Ocrevus launched for progressive MS, patients with progressive and advanced multiple sclerosis had not benefitted as much from therapeutic innovations in the MS space. Renowned neurologist, Robert Fox indicates that he always is very transparent with newly...